PROTARA THERAPEUTIC INC (TARA) Stock Price, Quote, News and Overview
NASDAQ:TARA - Nasdaq - US74365U1079 - Common Stock - Currency: USD
TARA Quote, Performance and Key Statistics
3.25
-0.23 (-6.61%)
The current stock price of TARA is 3.25 USD. In the past month the price decreased by -22.62%. In the past year, price increased by 16.07%.
TARA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.7 | 321.60B | ||
| AMGN | AMGEN INC | 13.07 | 145.89B | ||
| GILD | GILEAD SCIENCES INC | 13.92 | 134.11B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.91B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.65 | 65.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 38.06B | ||
| ARGX | ARGENX SE - ADR | 99.65 | 35.72B | ||
| ONC | BEIGENE LTD-ADR | 5.89 | 25.49B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.54B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.87B | ||
| BIIB | BIOGEN INC | 8.02 | 18.58B |
Related stock screener links
About TARA
Company Profile
Protara Therapeutics, Inc. is a clinical-stage company engaged in developing treatments for rare and specialty diseases with significant unmet needs. The company is headquartered in New York City, New York and currently employs 28 full-time employees. The company went IPO on 2014-10-22. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The firm is evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
Company Info
PROTARA THERAPEUTIC INC
345 Park Avenue South, 3rd Floor
New York City NEW YORK 10010 US
CEO: Jesse Shefferman
Employees: 31
Phone: 16468440337
PROTARA THERAPEUTIC INC / TARA FAQ
What is the stock price of PROTARA THERAPEUTIC INC today?
The current stock price of TARA is 3.25 USD. The price decreased by -6.61% in the last trading session.
What is the ticker symbol for PROTARA THERAPEUTIC INC stock?
The exchange symbol of PROTARA THERAPEUTIC INC is TARA and it is listed on the Nasdaq exchange.
On which exchange is TARA stock listed?
TARA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for PROTARA THERAPEUTIC INC stock?
12 analysts have analysed TARA and the average price target is 22.85 USD. This implies a price increase of 603.02% is expected in the next year compared to the current price of 3.25. Check the PROTARA THERAPEUTIC INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is PROTARA THERAPEUTIC INC worth?
PROTARA THERAPEUTIC INC (TARA) has a market capitalization of 125.39M USD. This makes TARA a Micro Cap stock.
How many employees does PROTARA THERAPEUTIC INC have?
PROTARA THERAPEUTIC INC (TARA) currently has 31 employees.
What are the support and resistance levels for PROTARA THERAPEUTIC INC (TARA) stock?
PROTARA THERAPEUTIC INC (TARA) has a support level at 3.18 and a resistance level at 3.49. Check the full technical report for a detailed analysis of TARA support and resistance levels.
Should I buy PROTARA THERAPEUTIC INC (TARA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TARA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TARA, evaluating the profitability, health, valuation and growth aspects
- PROTARA THERAPEUTIC INC (TARA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- PROTARA THERAPEUTIC INC (TARA) Sales and EPS estimates to see what analysts future expectations are.
- PROTARA THERAPEUTIC INC (TARA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- PROTARA THERAPEUTIC INC (TARA) Insider and Institutional Ownership to learn about the owners and their transactions.
- PROTARA THERAPEUTIC INC (TARA) Stock Chart to make your own analysis
- PROTARA THERAPEUTIC INC (TARA) Latest news and press-releases to stay up to date.
Does PROTARA THERAPEUTIC INC (TARA) stock pay dividends?
TARA does not pay a dividend.
When does PROTARA THERAPEUTIC INC (TARA) report earnings?
PROTARA THERAPEUTIC INC (TARA) will report earnings on 2025-08-04.
What is the Price/Earnings (PE) ratio of PROTARA THERAPEUTIC INC (TARA)?
PROTARA THERAPEUTIC INC (TARA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.73).
What is the Short Interest ratio of PROTARA THERAPEUTIC INC (TARA) stock?
The outstanding short interest for PROTARA THERAPEUTIC INC (TARA) is 6.65% of its float. Check the ownership tab for more information on the TARA short interest.
TARA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TARA. When comparing the yearly performance of all stocks, TARA turns out to be only a medium performer in the overall market: it outperformed 61.41% of all stocks.
TARA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TARA. TARA has a great financial health rating, but its profitability evaluates not so good.
TARA Financial Highlights
Over the last trailing twelve months TARA reported a non-GAAP Earnings per Share(EPS) of -1.73. The EPS increased by 53.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.58% | ||
| ROE | -26.68% | ||
| Debt/Equity | 0 |
TARA Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TARA. The Buy consensus is the average rating of analysts ratings from 12 analysts.